Tag Archives: AXGT

Chardan Capital Remains a Buy on Axovant Gene Therapies (AXGT)

Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Axovant Gene Therapies (AXGT – Research Report) on August 14 and set a price target of $12.50. The company’s shares closed last Friday at $3.05. According to TipRanks.com, Amusa is

Guggenheim Reiterates Buy on Axovant Gene Therapies Shares, Sees 699% Upside For The Stock

In a research report issued on Thursday, Guggenheim analyst Whitney Ijem reiterated a Buy rating on Axovant Gene Therapies (NASDAQ:AXGT)with a price target of $23, which implies an upside of 699% from current levels. According to TipRanks.com, which measures analysts’

Axovant Gene Therapies (AXGT) Receives an Outperform from Leerink Partners

In a report issued on June 10, Mani Foroohar from Leerink Partners reiterated an Outperform rating on Axovant Gene Therapies (NASDAQ: AXGT), with a price target of $12.00. The company’s shares closed last Friday at $2.88. Axovant Gene Therapies has

Cantor Fitzgerald Reiterates Overweight on Axovant Gene Therapies Shares, Sees 282% Upside For The Stock

In a research report released on 6/23, Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on Axovant Gene Therapies (NASDAQ:AXGT)with a price target of $11, which represents a potential upside of 282% from where the stock is currently trading.

Oppenheimer Remains a Hold on Axovant Gene Therapies (AXGT)

In a report released yesterday, Jay Olson from Oppenheimer maintained a Hold rating on Axovant Gene Therapies (AXGT – Research Report). The company’s shares closed last Wednesday at $3.45. According to TipRanks.com, Olson has 0 stars on 0-5 stars ranking

Axovant Gene Therapies (AXGT) Receives a Rating Update from a Top Analyst

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Axovant Gene Therapies (AXGT – Research Report), with a price target of $15.00. The company’s shares closed last Wednesday at $3.40. According to TipRanks.com, Amusa